TYRA Tyra Biosciences Inc
Company Analysis
Latest News
Tyra Biosciences Inc Q3 2026 Earnings Preview: What Analysts Expect on November 11, 2026
Tyra Biosciences is expected to report a Q3 2026 consensus loss of $0.66 per share on $0 revenue, with its current $21.15 share price trading significantly...
Tyra Biosciences Inc Q3 2026 Earnings Preview: What Analysts Expect on November 04, 2026
Tyra Biosciences is expected to report a Q3 2026 loss of $0.67 per share on zero revenue, with the current stock price of $21.52 trading significantly below...
TYRA Biosciences Announces Pricing of $400 Million Underwritten Public Offering
Tyra Biosciences, Inc. has entered into an underwriting agreement for a public offering of common stock and pre-funded warrants, with expected gross proceeds...
TYRA Announces Positive Phase 2 Data for Dabogratinib in Bladder Cancer Trial
Tyra Biosciences announced positive initial results from its SURF302 Phase 2 study of oral dabogratinib for treating FGFR3-altered non-muscle invasive bladder...
Farallon Capital Opens Major New $137M Position in Tyra Biosciences
Farallon Capital Management has established a new, significant stake in Tyra Biosciences (TYRA), a clinical-stage biotechnology company. According to its...
Farallon Capital exits TYRA Biosciences, liquidating $137M position
In a significant portfolio shift, Farallon Capital Management fully exited its position in TYRA Biosciences (TYRA), a clinical-stage biotech company. According...